June 2021  Vol. 377, No. 3

Contents

BEHAVIORAL PHARMACOLOGY

Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition
Chad R. Johnson, Brian D. Kangas, Emily M. Jutkiewicz, Gail Winger, Jack Bergman, Andrew Coop, and James H. Woods 336

CARDIOVASCULAR

Chronic Ca\(^{2+}\)/Calmodulin-Dependent Protein Kinase II Inhibition Rescues Advanced Heart Failure
Yixi Liu, Qun Shao, Heng-Jie Cheng, Tiankai Li, Xiaowei Zhang, Michael F. Callahan, David Herrington, Dalane Kitzman, David Zhao, and Che-Ping Cheng 316

Therapeutic Assessment of Combination Therapy with a Neprilysin Inhibitor and Angiotensin Type 1 Receptor Antagonist on Angiotensin II–Induced Atherosclerosis, Abdominal Aortic Aneurysms, and Hypertension
Yasir AlSiraj, Sean E. Thatcher, Ching Ling Liang, Heba Ali, Mark Ennor, and Lisa A. Cassis 326

CELLULAR AND MOLECULAR

circ-Keratin 6c Promotes Malignant Progression and Immune Evasion of Colorectal Cancer through microRNA-485-3p/Programmed Cell Death Receptor Ligand 1 Axis
Zhipeng Jiang, Zehui Hou, Wei Liu, Zhuomin Yu, Zhiqiang Liang, and Shuang Chen 358

Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide–Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C
Manuela Giansanti, Antonio De Gabrieli, Salvatore Pasquale Prete, Tiziana Ottone, Maria Domenica Divona, Terry Karimi, Fabio Ciccarese, Maria Teresa Voso, Grazia Graziani, and Isabella Faraoni 385

CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY

Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation
Qingxiang Lin, Zhicheng Qian, William J. Jusko, Donald E. Mager, Wen Wee Ma, and Robert M. Straubinger 370

DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine In Vivo Synergism
Young Hee Choi, Chao Zhang, Zhenzhun Liu, Mei-Juan Tu, Ai-Xi Yu, and Ai-Ming Yu 305

AM833 Is a Novel Agonist of Calcitonin Family G Protein–Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists
Madeleine M. Fletcher, Peter Keov, Tin T. Truong, Grace Mennen, Caroline A. Hick, Peishen Zhao, Sebastian G.B. Furness, Thomas Kruse, Trine R. Clausen, Denise Wootten, and Patrick M. Sexton 417

ENDOCRINE AND DIABETES

Ginsenoside Ro Ameliorates High-Fat Diet–Induced Obesity and Insulin Resistance in Mice via Activation of the G Protein–Coupled Bile Acid Receptor 5 Pathway
Lin-shan Jiang, Wei Li, Tong-xi Zhuang, Jie-jing Yu, Shuai Sun, Zheng-cai Ju, Zheng-tao Wang, Li-li Ding, and Li Yang 441
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL</td>
<td>Characterization of Novel Fluorescent Bile Salt Derivatives for Studying Human Bile Salt and Organic Anion Transporters</td>
<td>Michele Leuenberger, Stephanie Häusler, Vera Höhn, Adriana Euler, Bruno Stieger, and Martin Lochner</td>
</tr>
<tr>
<td>NEUROPHARMACOLOGY</td>
<td>Brain Concentrations of Methylone and Its Metabolites after Systemic Methylone Administration: Relationship to Pharmacodynamic Effects</td>
<td>Nicole Centazzo, Michael R. Chojnacki, Joshua S. Elmore, Raider Rodriguez, Teeshavi Acosta, Masaki Suzuki, Kenner C. Rice, Michael H. Baumann, and Marta Concheiro</td>
</tr>
<tr>
<td>LETTER TO THE EDITOR</td>
<td>Comments on “Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome”</td>
<td>Jolanta Skarbaliene, Bjarne Due Larsen, Mark Berner-Hansen, and Adam Steensberg</td>
</tr>
<tr>
<td>ERRATUM</td>
<td>Correction to “Pharmacological Characterization of Apraglutide, a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist, for the Treatment of Short Bowel Syndrome”</td>
<td></td>
</tr>
</tbody>
</table>

Supplemental material is available at jpet.aspetjournals.org.

About the cover: A new PK/PD model and strategy to evaluate combination therapy and define in vivo synergism. See the article by Choi et al. (dx.doi.org/10.1124/jpet.121.000584).